NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class (Descending) | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
70934-0634-82 | 70934-0634 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Aug. 18, 2020 | Aug. 31, 2023 | In Use |
70934-0634-84 | 70934-0634 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | July 13, 2021 | Jan. 31, 2025 | In Use |
70934-0634-95 | 70934-0634 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Aug. 31, 2020 | May 31, 2025 | In Use |
70934-0634-89 | 70934-0634 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb. 7, 2022 | Nov. 30, 2024 | In Use |
70934-0809-83 | 70934-0809 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | April 22, 2021 | Feb. 28, 2025 | In Use |
70934-0809-87 | 70934-0809 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | April 22, 2021 | Feb. 28, 2025 | In Use |
70934-0809-88 | 70934-0809 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Aug. 16, 2021 | Nov. 30, 2024 | In Use |
70934-0809-95 | 70934-0809 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Dec. 8, 2020 | Feb. 28, 2025 | In Use |
72162-1879-06 | 72162-1879 | Dronabinol | Dronabinol | 5.0 mg/1 | Ancillary Therapy | Antiemetic | CB1/CB2 | Oral | March 30, 2023 | In Use | |
72162-1880-06 | 72162-1880 | Dronabinol | Dronabinol | 10.0 mg/1 | Ancillary Therapy | Antiemetic | CB1/CB2 | Oral | March 30, 2023 | In Use | |
80425-0075-01 | 80425-0075 | Ondansetron HCL | Ondansetron HCL | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | July 31, 2007 | In Use | |
42043-0390-00 | 42043-0390 | Granisetron Hydrochloride | Granisetron Hydrochloride | 1.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | April 12, 2016 | In Use | |
42043-0390-02 | 42043-0390 | Granisetron Hydrochloride | Granisetron Hydrochloride | 1.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | April 12, 2016 | In Use | |
42043-0390-20 | 42043-0390 | Granisetron Hydrochloride | Granisetron Hydrochloride | 1.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | April 12, 2016 | In Use | |
42043-0390-21 | 42043-0390 | Granisetron Hydrochloride | Granisetron Hydrochloride | 1.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | April 12, 2016 | In Use | |
42043-0390-40 | 42043-0390 | Granisetron Hydrochloride | Granisetron Hydrochloride | 1.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | April 12, 2016 | In Use | |
42747-0726-01 | 42747-0726 | Granisetron | Sancuso | 3.1 mg/24h | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Transdermal | Sept. 12, 2008 | In Use | |
42747-0726-72 | 42747-0726 | Granisetron | Sancuso | 3.1 mg/24h | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Transdermal | Sept. 12, 2008 | In Use | |
70934-0294-84 | 70934-0294 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jan. 29, 2020 | Aug. 31, 2023 | No Longer Used |
70934-0294-95 | 70934-0294 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb. 22, 2019 | Aug. 31, 2023 | No Longer Used |
69543-0371-10 | 69543-0371 | Palonosetron hydrochloride | Palonosetron hydrochloride | 0.25 mg/5mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Sept. 19, 2018 | Jan. 31, 2026 | In Use |
52584-0069-00 | 52584-0069 | ONDANSETRON | ONDANSETRON | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | July 3, 2018 | Nov. 30, 2023 | No Longer Used |
60505-6105-01 | 60505-6105 | Fosaprepitant | Fosaprepitant | 150.0 mg/5mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Sept. 5, 2019 | Nov. 30, 2023 | No Longer Used |
00006-3061-00 | 00006-3061 | Fosaprepitant Dimeglumine | Emend | 150.0 mg/5mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Feb. 3, 2017 | In Use | |
00006-3061-01 | 00006-3061 | Fosaprepitant Dimeglumine | Emend | 150.0 mg/5mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Feb. 3, 2017 | In Use |
Found 10,000 results in 8 milliseconds — Export these results